DOGE Actions Begin to Trigger Shifts in D.C. Housing Market
North Bethesda, Md., June 24, 2025 (GLOBE NEWSWIRE) -- Federal workforce reductions under the Trump Administration's Department of Government Efficiency initiative are creating visible ripples across the Washington D.C. metro housing market. According to new data from Bright MLS, nearly 40% of real estate agents in the region reported working with clients in May whose decisions to buy or sell were directly tied to layoffs or federal buyout offers.
According to the survey, the housing market in the nation's capital, long known for its stability, is now facing a wave of inventory driven by early retirements and uncertainty among federal employees. The trend is putting downward pressure on prices and may signal a broader reshaping of homeownership patterns across the region.
'This spring marked a turning point for the Washington housing market,' said Lisa Sturtevant, Chief Economist at Bright MLS. 'Federal buyouts provided older, often higher-income homeowners a chance to cash out and relocate, but the ripple effects are just beginning. As more impacted families list homes post-school year, we could see further price pressure across the region this summer and fall.'
The Trump Administration's February buyout program offered up to eight months of salary and benefits to encourage federal workers to voluntarily resign. According to the Office of Personnel Management, approximately 75,000 employees accepted the offer.
Retirees lead the sell-off
The federal workforce cuts are not impacting all homeowners equally. The survey reveals that in the greater Washington D.C. region, 15% of spring home sales were due to retirement, compared to just 10% across the broader Bright MLS service area. Many of these retirees were federal employees with above-average incomes and fully paid-off homes, giving them the financial means and incentive to take buyout packages and transition out of the region ahead of potential further restructuring or job instability.
Prices under pressure
Although home prices in the D.C. area remain higher than national averages, agents are reporting growing price sensitivity and early signs of decline, with 38% indicating that workforce cuts are contributing to falling prices. Another 2% noted small price increases tied to tighter inventory in select pockets.
As inventory continues to rise, pricing power is shifting. Sellers are more likely to reduce asking prices or offer concessions to close deals. Agents also say that a second wave of listings is expected this summer, particularly from families waiting until after the school year to relocate.
Sales activity shifts
Over half (54%) of D.C.-area agents report that federal workforce reductions are affecting market activity, with 43% saying they've seen an uptick in sellers. A small number of agents (3%) reported seeing more buyers as a result of DOGE actions.
Market outlook
'Federal agencies have recently begun rehiring a limited number of laid-off workers, and no new cuts have been announced. However, with buyout payments ending later this summer, more selling activity may still be on the horizon,' Sturtevant said. 'By fall, the increase in inventory in the region could lead to flat or falling home prices in some markets in the region.'
The full report is available at www.BrightMLS.com/research
About Bright MLS
Bright MLS is the engine behind the nation's most dynamic real estate markets. As the largest multiple listing service in the U.S., Bright empowers over 100,000 real estate professionals with real-time data, deep market insights, and advanced tools. We support millions of showings annually on more than 425,000 properties listed across our primary markets in Delaware, Maryland, New Jersey, Pennsylvania, Virginia, West Virginia, and the District of Columbia—outpacing every other MLS in the country. With a nationally recognized research team and industry leading technology, Bright delivers trusted housing intelligence that guides smart decisions. Bright was built to lead, pushing organized real estate forward and creating a marketplace that is more transparent, competitive, and informed.
Christy Reap Bright MLS 2023099362 [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease
CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2 BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease, today announced it has received Pre-Investigational New Drug (Pre-IND) feedback from the U.S. Food and Drug Administration (FDA). The FDA reviewed the first-in-human trial design, including the Company's plan for dose escalation, proposed populations and safety monitoring plan. On the basis of the FDA feedback, the Company, intends to file an IND pending completion of final IND enabling studies. CUE-401 is the Company's lead autoimmune asset, a first-in-class bispecific fusion protein/molecule designed to induce and expand regulatory T cells (Tregs) in vivo through the co-activity of transforming growth factor beta (TGF-β) and a modified variant of interleukin 2 (IL-2). 'We are highly encouraged by the FDA's positive feedback on our proposed development plan for this important program. We believe CUE-401, with its first-in-class mechanism exploiting the combined activities of TGF-β and IL-2 is a potentially disruptive approach differentiated from other Treg-directed therapies, and has the potential to provide durable, long-lasting immune rebalance and tolerance addressing multiple, significant disease indications,' said Daniel Passeri, chief executive officer of Cue Biopharma. Dr. Dan Baker, chief development officer of Cue Biopharma commented, 'CUE-401's mechanistic design extends beyond nTreg proliferation by transforming effector/autoreactive responses to an anti-inflammatory and/or suppressive response, with the prospects of establishing tolerance. The combination of interleukin 2 (IL-2) and transforming growth factor beta (TGF-ß) is considered the 'master switch' for conversion of activated T effector cells into T cells with a regulatory phenotype.' About CUE-401CUE-401 is a preclinical, bispecific fusion protein designed to induce and expand regulatory T cells (Tregs) through the co-activity of modified variants of transforming growth factor beta (TGF-β) and interleukin 2 (IL-2) with therapeutic potential across a range of T-cell mediated autoimmune and inflammatory diseases. CUE-401 has been engineered to harness the Treg induction capacity of TGF-β combined with IL-2 signaling to provide what Cue Biopharma believes to be superior quality and stability of Tregs. The design and specifications of CUE-401 have been guided by leading scientific publications demonstrating that both IL-2 and TGF-β are required for stable and efficient production of active and durable Tregs. CUE-401 is designed to overcome multiple hurdles required to exploit the therapeutic potential of a master switch with a first-in-class, bispecific molecule integrating a masked TGF-ß, with our clinically validated, attenuated IL-2 with an antibody Fc fragment. This novel design provides for 'conditional binding' and avoids off target activity, simplifies manufacturing and has highly differentiated findings in multiple pre-clinical models. In these models, CUE-401 behaves as a master switch to convert autoreactive effector T cells (inflammatory cells) into stable, induced T-regulatory cells (iTregs). These findings suggest that CUE-401 acts by establishing a 'tolerance positive feedback loop' that not only increases nonspecific Treg populations, but critically, reduces and converts specific autoreactive T cells into transdifferentiated iTregs that are specific for the disease-causing autoantigens. About Cue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body. The company's proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body's intrinsic immune system without the adverse effects of broad systemic immune in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics. For more information please visit and follow us on X and LinkedIn. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the company's expectations regarding the planned IND filing for CUE-401; the Company' expectations regarding the potential characteristics and benefit of CUE-401; the company's belief that the Immuno-STAT platform stimulates targeted immune modulation through the selective modulation of disease-relevant T cell and the applicability of the company's platform across many cancers and autoimmune diseases; and the company's business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as 'believe,' 'expect,' 'may,' 'will,' 'should,' 'would,' 'could,' 'seek,' 'intend,' 'plan,' 'goal,' 'project,' 'estimate,' 'anticipate,' 'strategy,' 'future,' 'likely' or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's pipeline of product candidates and platforms, and its strategies, prospects, plans and objectives are forward-looking statements. Important factors that could cause the company's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the Company's ability to successfully advance is development plan for CUE-401; potential setbacks in the company's research and development efforts including negative or inconclusive results from its preclinical studies or clinical trials or the company's ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; its ability to secure required U.S. Food and Drug Administration ('FDA') or other governmental approvals for its product candidates, including FDA clearance of any future IND submission for CUE-401, and the breadth of any approved indication; adverse effects caused by public health pandemics, including possible effects on the company's trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company's reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company's ability to obtain adequate financing to fund its business operations in the near term; the company's ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company's most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Investor Contact Marie Campinell Senior Director, Corporate CommunicationsCue Biopharma, Media ContactJonathan PappasLifeSci Communicationsjpappas@
Yahoo
an hour ago
- Yahoo
FromZero.ai Launches Favicon Gallery, Targeting Guinness World Record for Largest Digital Mosaic
Interactive online mosaic invites users worldwide to permanently claim custom favicon tiles as part of a record-setting digital artwork San Francisco, California, June 24, 2025 (GLOBE NEWSWIRE) -- today announced the launch of Favicon Gallery, a large-scale digital mosaic project inviting users to permanently claim custom favicon tiles on an interactive online canvas. The project is aiming to set a Guinness World Record for the largest digital mosaic of favicons built in the shortest time. Favicon Gallery by — Guinness World Record mosaic in Gallery features a 100,000-tile digital canvas where each tile can be claimed for $99.99 USD. Participants upload their own favicon image, link, and title, contributing to a growing visual record of internet culture. The project is designed to encourage creativity, community engagement, and bold participation in digital spaces. Created as a public 'from zero' experiment without initial funding or code, Favicon Gallery reflects a philosophy of action over hesitation, demonstrating how ideas can be built openly and collaboratively online. 'Favicon Gallery is a live demonstration of how taking action can drive creativity and progress in the digital world,' said creator Sylvester M. 'We hope this inspires others to contribute, take creative risks, and become part of an evolving piece of internet history.' As the mosaic fills, will formally apply to Guinness World Records for recognition as the world's largest digital favicon mosaic created in the shortest timeframe. The long-term vision is for Favicon Gallery to generate funding that will support future digital ventures and creative innovation through open, community-driven projects. Favicon Gallery transforms the small, often-overlooked favicon, the tiny icon seen in browser tabs, into a platform for digital expression. Each tile in the mosaic represents permanent online real estate, owned and curated by individual participants. The project showcases contributions from creators, entrepreneurs, brands, and communities around the world. Built publicly from day one, Favicon Gallery emphasizes transparency and accessibility. Its development is openly documented on social channels and the project site. Current milestones include reaching 10,000–20,000 claimed tiles as the team builds momentum toward the Guinness World Record Favicon GalleryFavicon Gallery is an interactive digital mosaic created by The platform invites users worldwide to claim custom favicon tiles, contributing to a global artwork that celebrates creativity, internet culture, and bold claim a tile or learn more, visit: Sylvester M. Creator, contact@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
S&P 500 Gains and Losses Today: Coinbase Shares Soar; Oil and Defense Stocks Drop
The S&P 500 added 1.1% on Tuesday, June 24, 2025, as optimism spread about a possible de-escalation in the conflict between Israel and Iran. Coinbase shares surged, extending their solid rally as Benchmark analysts boosted their price target on the cryptocurrency exchange operator's stock. The potential for an alleviation of geopolitical tensions contributed to a drop in oil prices, pressuring oil and gas stocks, while aerospace and defense stocks also lost U.S. equities indexes gained ground on Tuesday after President Donald Trump announced a ceasefire agreement between Iran and Israel, raising hopes for a more sustained drawdown in hostilities. Investors also kept an eye on Congressional testimony by Federal Reserve Chair Jerome Powell. Powell indicated that the central bank intends to maintain interest rates at their current levels until there is more clarity on tariff policy and its potential economic impact, despite the White House's calls for immediate rate cuts. The S&P 500 gained 1.1%, closing just beneath its record-high level set in February. The Dow was up 1.2%, while the Nasdaq jumped 1.4%. Shares of Coinbase Global (COIN), operator of the largest cryptocurrency exchange in the U.S., skyrocketed 12.1% on Tuesday to secure the S&P 500's top performance. Analysts at the research firm Benchmark lifted their price target on Coinbase stock, pointing to favorable legislative and regulatory developments and the company's initiatives to capitalize on them. Secretary of Health and Human Services Robert F. Kennedy Jr. announced that the department would launch a massive advertising campaign to encourage the use of wearable health devices. Kennedy specifically mentioned the benefits of glucose monitors for patients managing diabetes. Shares of glucose monitor manufacturer Dexcom (DXCM) surged 9.7%. Uber Technologies (UBER) shares jumped 7.5% as the ridesharing company debuted its robotaxi service in Atlanta. Uber's partnership with Waymo, the autonomous vehicle company owned by Google parent Alphabet (GOOGL), initially offers service in 65 square miles of Atlanta, around half the city's footprint. Carnival Corporation (CCL) posted better-than-expected sales and profits for its fiscal first quarter, and the cruise operator's shares sailed 6.9% higher. The company also boosted its full-year profit outlook, pointing to increases in passengers carried and passenger cruise days as well as declining costs. Shares of competitors Norwegian Cruise Line Holdings (NCLH) and Royal Caribbean Group (RCL) also advanced. AutoZone (AZO) shares dropped 3.6%, losing the most of any S&P 500 stock on Tuesday, following reports that a senior vice president at the auto parts retailer had sold a stake in the company worth more than $2.5 million. Investors often view large sales by company insiders as a negative signal for a stock. Crude oil futures tumbled as optimism around de-escalation in the Middle East helped alleviate potential supply concerns. Shares of energy company Occidental Petroleum (OXY) fell 3.3%, while Exxon Mobil shares (XOM) were down 3%. The potential for calming geopolitical tensions also pressured defense stocks. Northrop Grumman (NOC) shares dropped 3.2%, while shares of aerospace and defense peers RTX Corp. (RTX) and Lockheed Martin (LMT) also traded lower. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
